Rare diseases
Investigational molecules
Locations
Luisenring J 5, 68159 Mannheim, Germany
Central Institute of Mental Health in Mannheim, Germany specialises in clinical trials of conditions such as Dementia Alzheimer's type, Schizophrenia, Alcohol use disorder, Major depression, and other specialisations. This site conducts important research.
The Central Institute of Mental Health in Mannheim is conducting clinical research in psychiatry and psychology, with a focus on mental disorders and the care of people living with schizophrenia. The studies are aimed at better understanding symptoms and evaluating whether new approaches can improve everyday functioning and cognitive health.
This research environment brings together clinical expertise and patient-centered investigation to support better treatment options in psychiatric care.
Clinical trials currently enrolling participants at this site.
A study of brenipatide compared to placebo for the treatment of adults with alcohol use disorder
GermanyStudy of xanomeline tartrate and trospium chloride combination for cognitive impairment in people with mild to moderate Alzheimer's disease
GermanyStudy of deupsilocin besilate (CYB003) in adults with major depressive disorder comparing two doses against placebo
GermanyLong-term safety and effectiveness study of CYB003 (deupsilocin besilate) with optional additional doses for people with Major Depressive Disorder
GermanyStudy on the Effects of Cannabidiol and Naltrexone on Alcohol Craving in Patients with Alcohol Dependence
GermanyStudy on Improving Social Skills in Schizophrenia Using Oxytocin or Placebo as an Add-On Treatment for Patients with Schizophrenia Spectrum Disorders
GermanyStudy on the Benefits of Amyloid PET Imaging with Florbetaben (18F) and Flutemetamol (18F) for Patients with Various Types of Dementia
GermanyA study to evaluate the effectiveness and safety of AP707 in patients with borderline personality disorder.
GermanyGermanyStudy on Thiethylperazine and Florbetaben (18F) for Early Alzheimer's Disease Patients
GermanyStudy on the Effects of Sabirnetug for Patients with Early Alzheimer's Disease
GermanyStudy on Cannabidiol as an Add-On Treatment for Patients with Early Schizophrenia
GermanyMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
